

John H Sampson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2444550/john-h-sampson-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330
papers

22,275
citations

80
h-index

139
g-index

359
ext. papers

25,722
ext. citations

5.8
avg, IF

6.72
L-index

#	Paper	IF	Citations
330	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vdac025 ^{0.9}		2
329	Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype.. <i>Methods in Molecular Biology</i> , 2022 , 2410, 609-626	1.4	
328	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma 2021 , 9,		1
327	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. <i>Cancers</i> , 2021 , 13,	6.6	3
326	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3916-3925	12.9	4
325	Targeting Immunometabolism in Glioblastoma. <i>Frontiers in Oncology</i> , 2021 , 11, 696402	5.3	5
324	Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. <i>Journal of Neuro-Oncology</i> , 2021 , 151, 55-62	4.8	21
323	A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. <i>Npj Vaccines</i> , 2021 , 6, 12	9.5	2
322	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy 2021 , 635-665		
321	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021 , 12, 352	17.4	31
320	CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL. <i>Neuro-Oncology Advances</i> , 2021 , 3, iv3-iv3	0.9	78
319	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
318	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
317	Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study.. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100760	3.3	2
316	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1003-1010	13.4	328
315	Comparative study of Helical and Sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. <i>Biomaterials Science</i> , 2020 , 8, 3522-3535	7.4	20
314	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020 , 26, 5287-5296	12.9	48

313	Oncolytic virus-derived type I interferon restricts CAR T cell therapy. <i>Nature Communications</i> , 2020 , 11, 3187	17.4	24
312	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 579-591	5.4	21
311	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1586-1594	12.9	56
310	Current multidisciplinary management of brain metastases. <i>Cancer</i> , 2020 , 126, 1390-1406	6.4	28
309	First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach 2020 , 8,		10
308	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2020 , 130, 774-788	15.9	18
307	MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2513-2513	2.2	3
306	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2566-2566	2.2	2
305	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020 , 20, 12-25	31.3	174
304	Determinants of Intraparenchymal Infusion Distributions: Modeling and Analyses of Human Glioblastoma Trials. <i>Pharmaceutics</i> , 2020 , 12,	6.4	7
303	GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody. <i>PLoS ONE</i> , 2020 , 15, e0236374	3.7	4
302	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5297-5303	12.9	26
301	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1147-1158	3.8	3
300	The current state of immunotherapy for gliomas: an eye toward the future. <i>Journal of Neurosurgery</i> , 2019 , 131, 657-666	3.2	48
299	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019 , 25, 6570-6580	12.9	38
298	Reply to Q Assembling the brain trust: the multidisciplinary imperative in neuro-oncologyQ <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 522-523	19.4	
297	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. <i>Cancer Research</i> , 2019 , 79, 3383-3394	10.1	16
296	A Review of Anesthesia Simulation in Low-Income Countries. <i>Current Anesthesiology Reports</i> , 2019 , 9, 1-9	1	4

295	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 509-520	19.4	284
294	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4202-4210	12.9	96
293	Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach. <i>Journal of Proteome Research</i> , 2019 , 18, 3032-3041	5.6	8
292	MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2039-2039	2.2	3
291	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2060-2060	2.2	1
290	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13526-e13526	2.2	4
289	The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 30-30	2.2	
288	ATIM-30. COMBATING RECURRENT GLIOBLASTOMA WITH MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, THROUGH MRI-GUIDED CONVECTIVE DELIVERY. <i>Neuro-Oncology</i> , 2019 , 21, vi8-vi8	1	1
287	PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019 , 21, vi185-vi185	1	78
286	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2019 , 21, vi6-vi6	1	1
285	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. <i>Neuro-Oncology</i> , 2019 , 21, vi7-vi7	1	3
284	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019 , 21, vi8-vi8	1	78
283	EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019 , 21, vi84-vi84	1	78
282	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , 2019 , 21, vi12-vi12	1	3
281	Effective effectors: How T cells access and infiltrate the central nervous system. <i>Pharmacology & Therapeutics</i> , 2019 , 197, 52-60	13.9	7
280	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. <i>Clinical Cancer Research</i> , 2019 , 25, 2042-2048	12.9	43
279	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. <i>Clinical Cancer Research</i> , 2019 , 25, 358-368	12.9	41
278	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. <i>OncolImmunology</i> , 2018 , 7, e1434464	7.2	48

277	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018 , 20, 674-686	1	233
276	Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving?. <i>Neurosurgery</i> , 2018 , 83, 1269-1276	3.2	10
275	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. <i>Clinical Cancer Research</i> , 2018 , 24, 3611-3631	13.9	29
274	Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. <i>Journal of Clinical Neuroscience</i> , 2018 , 56, 163-168	2.2	17
273	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. <i>Nature Medicine</i> , 2018 , 24, 1459-1468	50.5	253
272	Introduction. Update on adult neuro-oncology. <i>Neurosurgical Focus</i> , 2018 , 44, E1	4.2	
271	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. <i>Cancer Research</i> , 2018 , 78, 256-264	10.1	53
270	ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi1-vi2	1	1
269	DDIS-02. NOVEL BISPECIFIC ACTIVATOR OF MACROPHAGES FOR THE TREATMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi69-vi69	1	78
268	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2018 , 20, vi9-vi9	1	1
267	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. <i>Neuro-Oncology</i> , 2018 , 20, vi7-vi7	1	78
266	RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi234-vi234	1	78
265	CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. <i>OncImmunology</i> , 2018 , 7, e1502904	7.2	6
264	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. <i>Neuro-Oncology</i> , 2018 , 20, i93-i93	1	2
263	A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. <i>Journal of Immunological Methods</i> , 2018 , 459, 90-93	2.5	4
262	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018 , 379, 150-161	59.2	363
261	Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors 2018 , 693-705		
260	Immunotherapy for High-Grade Gliomas 2017 , 177-192		

259	Prospect of rindopepimut in the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 507-513	5.4	28
258	The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 83-87	4.8	1
257	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017 , 23, 1898-1909	12.9	152
256	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017 , 13, 363-374	15	82
255	Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. <i>Neuro-Oncology</i> , 2017 , 19, 1391-1397	1	21
254	Immunomodulation for glioblastoma. <i>Current Opinion in Neurology</i> , 2017 , 30, 361-369	7.1	14
253	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 277-287	4.1	15
252	Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 1049-1060	5.1	47
251	Single fraction stereotactic radiosurgery for multiple brain metastases. <i>Advances in Radiation Oncology</i> , 2017 , 2, 555-563	3.3	29
250	Immunotherapy for Brain Tumors. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2450-2456	2.2	73
249	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1373-1385	21.7	518
248	A Supramolecular Vaccine Platform Based on β -Helical Peptide Nanofibers. <i>ACS Biomaterials Science and Engineering</i> , 2017 , 3, 3128-3132	5.5	51
247	Accuracy of Novel Computed Tomography-Guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers. <i>World Neurosurgery</i> , 2017 , 106, 757-763	2.1	2
246	Obituary. Robert H. Wilkins, MD, 1934-2017. <i>Journal of Neurosurgery</i> , 2017 , 127, 1457-1458	3.2	
245	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - AuthorsReply. <i>Lancet Oncology</i> , 2017 , 18, e709-e710	21.7	4
244	Advances and challenges: dendritic cell vaccination strategies for glioblastoma. <i>Expert Review of Vaccines</i> , 2017 , 16, 27-36	5.2	22
243	Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. <i>Oncot Immunology</i> , 2017 , 6, e1256527	7.2	36
242	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13532-e13532	2.2	2

241	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13533-e13533	2.2	
240	Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. <i>Clinical Cancer Research</i> , 2016 , 22, 5164-5166	12.9	9
239	Delivering therapy to target: improving the odds for successful drug development. <i>Therapeutic Delivery</i> , 2016 , 7, 457-81	3.8	20
238	Advances in Immunotherapy: Abhijit Guha Award Presentation. <i>Neurosurgery</i> , 2016 , 63 Suppl 1, 85-87	3.2	1
237	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 205-11	7.4	5
236	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <i>Clinical Cancer Research</i> , 2016 , 22, 582-95	12.9	61
235	Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2014-2014	2.2	21
234	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2061-2061	2.2	11
233	Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e13518-e13518	2.2	2
232	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2061-2061	2.2	26
231	ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143. <i>Neuro-Oncology</i> , 2016 , 18, vi21-vi21	1	6
230	Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. <i>Cancer Research</i> , 2016 , 76, 5143-50	10.1	21
229	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRVIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016 , 18, vi17-vi18	1	29
228	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 133-45	3.7	29
227	Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. <i>Methods in Molecular Biology</i> , 2016 , 1403, 819-38	1.4	5
226	Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 419-27	7.4	119
225	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015 , 519, 366-9	50.4	333
224	Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. <i>Journal of Visualized Experiments</i> , 2015 ,	1.6	13

223	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology, The</i> , 2015 , 16, e534-e542	21.7	425
222	Vaccination strategies for neuro-oncology. <i>Neuro-Oncology</i> , 2015 , 17 Suppl 7, vii15-vii25	1	21
221	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015 , 11, 504-14	15	240
220	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , 2015 , 133, 730-8	6	10
219	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 65-74	7.8	12
218	Are BiTEs the "missing link" in cancer therapy?. <i>Oncolmmunology</i> , 2015 , 4, e1008339	7.2	49
217	miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment. <i>Oncolmmunology</i> , 2015 , 4, e990803	7.2	11
216	Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. <i>Cancer Immunology Research</i> , 2015 , 3, 320-5	12.5	16
215	Peptide vaccines for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 123, 433-40	4.8	26
214	Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 100-8	4	88
213	Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 79-94	5.4	14
212	IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143. <i>Neuro-Oncology</i> , 2015 , 17, v107.3-v107	1	6
211	IMCT-19COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). <i>Neuro-Oncology</i> , 2015 , 17, v111.4-v112	1	78
210	107 ReACT. <i>Neurosurgery</i> , 2015 , 62, 198-199	3.2	15
209	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. <i>Oncolmmunology</i> , 2015 , 4, e994374	7.2	29
208	Immunotherapy for malignant glioma. <i>Surgical Neurology International</i> , 2015 , 6, S68-77	1	31
207	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v109.1-v109	1	17
206	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015 , 17, 854-61	1	257

205	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2009-2009	2.2	45
204	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2068-2068	2.2	7
203	Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3010-3010	2.2	42
202	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13030-e13030	2.2	
201	EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. <i>Clinical Cancer Research</i> , 2014 , 20, 972-84	12.9	205
200	Epidermal growth factor receptor and variant III targeted immunotherapy. <i>Neuro-Oncology</i> , 2014 , 16 Suppl 8, viii20-5	1	22
199	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014 , 16, 1441-58	1	136
198	Antibody-based immunotherapy for malignant glioma. <i>Seminars in Oncology</i> , 2014 , 41, 496-510	5.5	11
197	A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. <i>Journal of Neurosurgery</i> , 2014 , 121, 536-42	3.2	19
196	Oncolytic polio virotherapy of cancer. <i>Cancer</i> , 2014 , 120, 3277-86	6.4	48
195	Recurrent malignant gliomas. <i>Seminars in Radiation Oncology</i> , 2014 , 24, 289-98	5.5	32
194	Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. <i>Journal of Clinical Neuroscience</i> , 2014 , 21, 189-90	2.2	85
193	EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. <i>PLoS ONE</i> , 2014 , 9, e94281	3.7	85
192	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. <i>Oncolimmunology</i> , 2014 , 3, e944054	7.2	13
191	Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. <i>Oncolimmunology</i> , 2014 , 3, e944059	7.2	7
190	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2047-61	4	16
189	Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions. <i>Journal of Neurosurgery</i> , 2014 , 121, 262-76	3.2	43
188	Immunological targeting of cytomegalovirus for glioblastoma therapy. <i>Oncolimmunology</i> , 2014 , 3, e29289.2	7.2	17

187	Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. <i>Immunotherapy</i> , 2014 , 6, 679-90	3.8	68
186	Impact of PhD training on scholarship in a neurosurgical career. <i>Journal of Neurosurgery</i> , 2014 , 120, 730-5	2	26
185	Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. <i>Clinical Cancer Research</i> , 2014 , 20, 2684-94	12.9	57
184	Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. <i>Journal of Clinical Investigation</i> , 2014 , 124, 5352-67	15.9	82
183	Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. <i>Journal of Radiosurgery and SBRT</i> , 2014 , 3, 37-42	0.4	3
182	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. <i>Expert Review of Clinical Pharmacology</i> , 2013 , 6, 375-86	3.8	17
181	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. <i>Future Oncology</i> , 2013 , 9, 977-90	3.6	19
180	BLYS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 983-7	7.4	12
179	Radiotherapy and radiosurgery for tumors of the central nervous system. <i>Surgical Oncology Clinics of North America</i> , 2013 , 22, 445-61	2.7	8
178	Enhanced oncolytic virotherapy through oxidative stress inhibition. <i>Molecular Therapy</i> , 2013 , 21, 1981-3	11.7	
177	A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1649-62	7.4	7
176	Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. <i>Cancer Immunology Research</i> , 2013 , 1, 163	12.5	43
175	Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 873-9	4	82
174	Clinicopathological characteristics and treatment of rhabdoid glioblastoma. <i>Journal of Neurosurgery</i> , 2013 , 119, 412-9	3.2	20
173	Complete response to steroids in dural inflammatory pseudotumor associated with Still@ disease. <i>Journal of Clinical Neuroscience</i> , 2013 , 20, 1445-8	2.2	1
172	Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. <i>Cancer Treatment Reviews</i> , 2013 , 39, 261-9	14.4	59
171	Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. <i>Journal of Immunological Methods</i> , 2013 , 395, 14-20	2.5	4
170	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , 2013 , 12, 597-615	5.2	49

169	Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. <i>Journal of Neurosurgery</i> , 2013 , 118, 1176-80	3.2	17
168	Thickness of subcutaneous fat as a risk factor for infection in cervical spine fusion surgery. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013 , 95, 323-8	5.6	70
167	A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. <i>OncolImmunology</i> , 2013 , 2, e23639	7.2	15
166	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. <i>OncolImmunology</i> , 2013 , 2, e26757	7.2	27
165	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 270-5 ^{11.5}		95
164	Contemporary surgical management of vestibular schwannomas: analysis of complications and lessons learned over the past decade. <i>Operative Neurosurgery</i> , 2013 , 72, ons103-15; discussion ons115	1.6	40
163	Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. <i>PLoS ONE</i> , 2013 , 8, e59082	3.7	50
162	Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3135-45	15.9	48
161	Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. <i>Drugs of the Future</i> , 2013 , 38, 147-155	2.3	17
160	Phase II study of Gleevec [®] plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 409-15	4.8	62
159	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 155-64	4.8	108
158	Regulatory T cells move in when gliomas say "I Do". <i>Clinical Cancer Research</i> , 2012 , 18, 6086-8	12.9	11
157	Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 58-66	4	61
156	Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 2018-24	4.4	132
155	Enzyme redesign guided by cancer-derived IDH1 mutations. <i>Nature Chemical Biology</i> , 2012 , 8, 887-9	11.7	14
154	The limitations of imaging response criteria. <i>Lancet Oncology</i> , 2012 , 13, 1064-5	21.7	1
153	The use of motor mapping to aid resection of eloquent gliomas. <i>Neurosurgery Clinics of North America</i> , 2012 , 23, 215-25, vii	4	8
152	A pilot study of IL-2R α blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. <i>PLoS ONE</i> , 2012 , 7, e31046	3.7	84

151	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 499-506	4.8	36
150	Clinical data simplified. <i>Journal of Neurosurgery</i> , 2012 , 116, 346-8; discussion 348	3.2	1
149	Toxin-based targeted therapy for malignant brain tumors. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 480429		20
148	Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. <i>Neurosurgery</i> , 2012 , 70, 234-43; discussion 243-4	3.2	159
147	Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 695-9	7.3	20
146	Immunotherapy with tumor vaccines for the treatment of malignant gliomas. <i>Current Drug Discovery Technologies</i> , 2012 , 9, 237-55	1.5	4
145	Convection enhanced delivery of macromolecules for brain tumors. <i>Current Drug Discovery Technologies</i> , 2012 , 9, 305-10	1.5	23
144	Monitoring radiographic brain tumor progression. <i>Toxins</i> , 2011 , 3, 191-200	4.9	23
143	Imaging of convection enhanced delivery of toxins in humans. <i>Toxins</i> , 2011 , 3, 201-6	4.9	18
142	A novel method for volumetric MRI response assessment of enhancing brain tumors. <i>PLoS ONE</i> , 2011 , 6, e16031	3.7	36
141	Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. <i>Neurosurgery</i> , 2011 , 69, 668-76	3.2	64
140	Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. <i>Blood</i> , 2011 , 118, 3003-12	2.2	87
139	A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 414-27	7.3	95
138	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
137	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 57-66	4.8	104
136	Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 267-77	4.8	60
135	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 371-9	4.8	72
134	Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Cancer</i> , 2011 , 117, 5351-8	6.4	71

133	Bispecific antibodies engage T cells for antitumor immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 843-53	5.4	66
132	Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. <i>Neuro-Oncology</i> , 2011 , 13, 3-13	1	84
131	Low-grade glioma. <i>Journal of Neurosurgery</i> , 2011 , 114, 563-4; discussion 564-5	3.2	1
130	Resection of vestibular schwannomas. <i>Journal of Neurosurgery</i> , 2011 , 114, 1216-7; discussion 1217	3.2	2
129	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 324-33	1	241
128	Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, e739-42	2.2	21
127	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2011 , 29, e519-e520	2.2	1
126	The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. <i>Clinical Cancer Research</i> , 2011 , 17, 4119-24	12.9	119
125	Is cytomegalovirus a therapeutic target in glioblastoma?. <i>Clinical Cancer Research</i> , 2011 , 17, 4619-21	12.9	23
124	Reply to M.S. Lesniak. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3105-3106	2.2	9
123	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011 , 13, 353-61	1	90
122	Malignant Glioma Immunotherapy: A Peptide Vaccine from Bench to Bedside 2011 , 349-356		
121	Stereotactic radiosurgery in the treatment of a dural carotid-cavernous fistula. <i>Journal of Neuro-Ophthalmology</i> , 2010 , 30, 138-44	2.6	4
120	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4722-9	2.2	593
119	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 871-81	1	338
118	Poor drug distribution as a possible explanation for the results of the PRECISE trial. <i>Journal of Neurosurgery</i> , 2010 , 113, 301-9	3.2	186
117	The role of tregs in glioma-mediated immunosuppression: potential target for intervention. <i>Neurosurgery Clinics of North America</i> , 2010 , 21, 125-37	4	45
116	Clinical applications of a peptide-based vaccine for glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2010 , 21, 95-109	4	15

115	Immunotherapy approaches for malignant glioma from 2007 to 2009. <i>Current Neurology and Neuroscience Reports</i> , 2010 , 10, 259-66	6.6	37
114	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 1-7	4.8	44
113	Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 427-30	4.8	6
112	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010 , 96, 219-30	4.8	172
111	Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321. <i>Neurological Research</i> , 2010 , 32, 810-5	2.7	8
110	Convection-Enhanced Drug Delivery to the Brain. <i>Neuromethods</i> , 2010 , 291-318	0.4	3
109	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2773-9	6.1	209
108	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1262-7	2.2	226
107	Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2009 , 15, 1064-8	12.9	50
106	The PEPVIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 1087-98	5.4	67
105	Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2009 , 11, 556-61	1	26
104	IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. <i>International Journal of Cancer</i> , 2009 , 125, 680-7	7.5	67
103	Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. <i>Cancer</i> , 2009 , 115, 2964-70	6.4	25
102	Toward effective immunotherapy for the treatment of malignant brain tumors. <i>Neurotherapeutics</i> , 2009 , 6, 527-38	6.4	33
101	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009 , 95, 393-400	4.8	37
100	EGFRVIII-targeted vaccination therapy of malignant glioma. <i>Brain Pathology</i> , 2009 , 19, 713-23	6	107
99	A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. <i>Journal of Neurochemistry</i> , 2009 , 109, 1079-86	6	70
98	Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 73, 1369-75	4	93

97	Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. <i>Nuclear Medicine and Biology</i> , 2009 , 36, 659-69	2.1	35
96	Proteomic and immunologic analyses of brain tumor exosomes. <i>FASEB Journal</i> , 2009 , 23, 1541-57	0.9	315
95	Paraganglioma of the head and neck: long-term local control with radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 304-7	2.7	50
94	Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. <i>Journal of Immunological Methods</i> , 2008 , 339, 74-81	2.5	41
93	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. <i>Seminars in Immunology</i> , 2008 , 20, 267-75	10.7	133
92	Selective modification of antigen-specific T cells by RNA electroporation. <i>Human Gene Therapy</i> , 2008 , 19, 511-21	4.8	37
91	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. <i>Neuro-Oncology</i> , 2008 , 10, 320-9	1	160
90	Combating immunosuppression in glioma. <i>Future Oncology</i> , 2008 , 4, 433-42	3.6	47
89	Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 717-32	3.5	8
88	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. <i>Neuro-Oncology</i> , 2008 , 10, 98-103	1	98
87	Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. <i>Clinical Cancer Research</i> , 2008 , 14, 7068-73	12.9	152
86	Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 10-8	1	285
85	A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. <i>Clinical Cancer Research</i> , 2008 , 14, 5759-68	12.9	97
84	Cholesterol granuloma of the lateral ventricle. Case report. <i>Journal of Neurosurgery</i> , 2008 , 108, 357-60	3.2	6
83	Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. <i>Journal of Neurosurgery</i> , 2008 , 109, 874-80	3.2	82
82	Cryptococcal meningitis in patients with glioma: a report of two cases. <i>Journal of Neuro-Oncology</i> , 2008 , 89, 51-3	4.8	21
81	EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 115-21	7.4	36
80	Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. <i>Neurosurgical Review</i> , 2008 , 31, 141-55; discussion 155	3.9	32

79	Immunotherapy of malignant brain tumors. <i>Immunological Reviews</i> , 2008 , 222, 70-100	11.3	73
78	Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. <i>Journal of Neuroimmunology</i> , 2007 , 182, 63-72	3.5	7
77	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007 , 83, 53-60	4.8	87
76	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4722-9	2.2	1119
75	Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. <i>American Journal of Roentgenology</i> , 2007 , 188, 703-9	5.4	61
74	Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. <i>Neuro-Oncology</i> , 2007 , 9, 343-53	1	101
73	Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 837-44	2.2	285
72	Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. <i>Clinical Cancer Research</i> , 2007 , 13, 2158-67	12.9	235
71	Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. <i>Operative Neurosurgery</i> , 2007 , 60, ONS89-98; discussion ONS98-9	1.6	85
70	Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. <i>Neurosurgery</i> , 2007 , 61, 1031-7; discussion 1037-8	3.2	114
69	Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. <i>Clinical Cancer Research</i> , 2006 , 12, 4294-305	12.9	132
68	Convection-enhanced delivery of therapeutics for brain disease, and its optimization. <i>Neurosurgical Focus</i> , 2006 , 20, E12	4.2	177
67	Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. <i>Clinical Cancer Research</i> , 2006 , 12, 860-8	12.9	173
66	Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. <i>Clinical Cancer Research</i> , 2006 , 12, 7306-15	12.9	57
65	Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. <i>Neurosurgical Focus</i> , 2006 , 20, E14	4.2	50
64	Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. <i>Cancer Research</i> , 2006 , 66, 3294-302	10.1	430
63	Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. <i>Clinical Cancer Research</i> , 2006 , 12, 1349-54	12.9	47
62	Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. <i>Radiology</i> , 2006 , 240, 793-802	20.5	173

61	Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. <i>Neurologia Medico-Chirurgica</i> , 2006 , 46, 485-9; discussion 489-90	2.6	6
60	Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. <i>Neurosurgical Focus</i> , 2006 , 20, E15	4.2	62
59	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 912-8	8.9	32
58	Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9359-68	2.2	286
57	Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. <i>Neurosurgery</i> , 2005 , 56, 546-59; discussion 546-59	3.2	198
56	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. <i>Neuro-Oncology</i> , 2005 , 7, 90-6	1	43
55	Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7178-87	2.2	174
54	Brain Metastases from Malignant Melanoma 2005 , 430-438		2
53	Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2004 , 10, 3216-24	12.9	137
52	Phase II trial of gefitinib in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 133-42	2.2	607
51	Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. <i>Neuro-Oncology</i> , 2004 , 6, 145-53	1	19
50	Poliovirus receptor CD155-targeted oncolysis of glioma. <i>Neuro-Oncology</i> , 2004 , 6, 208-17	1	87
49	Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. <i>Clinical Cancer Research</i> , 2004 , 10, 4831-8	12.9	41
48	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004 , 6, 134-44	1	32
47	How does the immune system attack cancer?. <i>Current Problems in Surgery</i> , 2004 , 41, 15-132	2.8	12
46	Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance. <i>Neurosurgery</i> , 2004 , 54, 884-9; discussion 889-90	3.2	100
45	Novel Therapeutic Approaches for High-Grade Gliomas. <i>Frontiers in Neuroscience</i> , 2004 , 155-180		
44	Phase II trial of temozolomide in patients with progressive low-grade glioma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 646-51	2.2	218

43	Adoptive immunotherapy for malignant glioma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003 , 9, 157-66	2.2	19
42	The History, Evolution, and Clinical use of Dendritic Cell-Based Immunization Strategies in the Therapy of Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 64, 161-176	4.8	4
41	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 65, 27-35	4.8	198
40	The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 64, 161-76	4.8	30
39	Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 4247-54	12.9	163
38	Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 5514-20	12.9	54
37	Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1389-97	2.2	206
36	Generation of anti-idiotypic reagents in the EGFRVIII tumor-associated antigen system. <i>Cancer Immunology, Immunotherapy</i> , 2002 , 50, 639-52	7.4	19
35	Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2277-83	2.2	156
34	Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. <i>Neurosurgery</i> , 2002 , 50, 158-64; discussion 164-6	3.2	67
33	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. <i>Neurosurgery</i> , 2002 , 50, 158-166	3.2	60
32	Clinical immunotherapy for brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002 , 12, 641-64	3	9
31	Viruses in the treatment of brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002 , 12, 553-70	3	7
30	Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. <i>Cancer Research</i> , 2002 , 62, 3335-9	10.1	189
29	Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). <i>Clinical Cancer Research</i> , 2002 , 8, 3496-502	12.9	120
28	Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. <i>Neuro-Oncology</i> , 2001 , 3, 246-50	1	35
27	Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. <i>Journal of Neuroimmunology</i> , 2000 , 103, 16-25	3.5	109
26	Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3522-8	2.2	111

25	Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 7503-8	11.5	160
24	EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types. <i>Expert Opinion on Therapeutic Targets</i> , 2000 , 4, 497-514		5
23	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. <i>Journal of Neuro-Oncology</i> , 1999 , 44, 233-41	4.8	15
22	Monoclonal antibody therapy of human gliomas: current status and future approaches. <i>Cancer and Metastasis Reviews</i> , 1999 , 18, 451-64	9.6	46
21	Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. <i>Journal of Neuroimmunology</i> , 1998 , 86, 46-52	3.5	26
20	Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. <i>Journal of Neurosurgery</i> , 1998 , 88, 11-20	3.2	401
19	Cytokine-Based Gene Therapy for Brain Tumors 1998 , 231-294		1
18	Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. <i>Neurosurgery</i> , 1997 , 41, 1365-72; discussion 1372-3	3.2	79
17	A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. <i>Journal of Neuroimmunology</i> , 1997 , 78, 34-46	3.5	31
16	Recurrence of a cerebral arteriovenous malformation after surgical excision. Case report. <i>Journal of Neurosurgery</i> , 1996 , 84, 879-82	3.2	66
15	Dorsal root entry zone lesions for intractable pain after trauma to the conus medullaris and cauda equina. <i>Journal of Neurosurgery</i> , 1995 , 82, 28-34	3.2	40
14	Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. <i>Spine</i> , 1995 , 20, 2141-6	3.3	30
13	The gravitational shunt: an alternative approach to cerebrospinal fluid shunting. <i>World Neurosurgery</i> , 1993 , 40, 112-8		1
12	Facial pain due to vascular lesions of the brain stem relieved by dorsal root entry zone lesions in the nucleus caudalis. Report of two cases. <i>Journal of Neurosurgery</i> , 1992 , 77, 473-5	3.2	12
11	Solitary Eosinophilic Granuloma Invading the Clivus of an Adult. <i>Neurosurgery</i> , 1992 , 31, 755-757	3.2	9
10	Solitary eosinophilic granuloma invading the clivus of an adult: case report. <i>Neurosurgery</i> , 1992 , 31, 755-7; discussion 757-8	3.2	15
9	Design and statistical analysis of clinical trials for glioma therapy 169-189		
8	Radiation therapy for gliomas 49-75		

7 Immunotherapy for gliomas91-120

6 Neuropathology of gliomas146-168

5 Health-related quality of life in glioma patients190-204

4 Chemotherapy for gliomas76-90

3 Glioma surgery24-48

2 Neuroradiology of gliomas121-145

1 Genetics of glioma1-23

1